J&J Submits Dapoxetine NDA For Premature Ejaculation
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is waiting to see if the selective serotonin reuptake inhibitor will receive priority review. Submission is slightly earlier than expected.